Vitedoamine A 

Vitedoamine A is a Phenylnaphthalene-type lignan alkaloid. Vitedoamine A can be isolated from Vitex negundo. Vitedoamine A inhibits the activity of IKKβ with an IC₅₀ value of 39 μM. Vitedoamine A could inhibit the transcriptional activity of NF-κB, and suppress the production of NO and reduce the expressions of inflammatory cytokines (IL-1β, IL-6, and TNF-α). Vitedoamine A inhibits the phosphorylation of IKKα/β and p65, and prevents the degradation of IκBα. Vitedoamine A possesses anti-rheumatoid arthritis capacity^[1].

Vitedoamine A (5-60 μM) directly targets IKKβ and inhibits its enzymatic activity, with an IC₅₀ of 39 μM^[1].
Vitedoamine A (1-80 μM; 48 h for cell viability assay) dose-dependently inhibits NF-κB transcriptional activity in TNF-α-stimulated 293 T cells without reducing cell viability^[1].
Vitedoamine A (1-40 μM; 4 h) inhibits the activation of NF-κB by suppressing LPS/TNF-α-induced phosphorylation of IKKα/β in RAW264.7 cells^[1].
Vitedoamine A (1-40 μM; 4 h) exerts anti-rheumatoid arthritis (RA) activity in IL-1β-stimulated human fibroblast-like synoviocytes by targeting IKKβ to inhibit NF-κB pathway activation and reduce the production of proinflammatory cytokines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

351.35

C₂₀H₁₇NO₅

819861-41-1

O=C1NCC2=C1C=C3C=C(C(O)=CC3=C2C4=CC(OC)=C(O)C=C4)OC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bai B, et al. Discovery of a lignan alkaloid, vitedoamine A, as an IKKβ inhibitor for suppressing NF-κB mediated inflammatory responses and osteoclastogenesis in rheumatoid arthritis. Fitoterapia. 2025;182:106482.  [Content Brief]